Summary.-The cell-mediated cytotoxicity (CMC) of blood mononuclear cells against cultured human melanoma cells was measured in patients after surgical removal of localized melanoma, at a time when they were considered on clinical grounds to be free of melanoma. It was found that the distribution of CMC values against melanoma cells in melanoma patients was different from that in control subjects, and several sub-populations of melanoma patients were evident on the basis of these measurements. No difference in distribution of CMC values was found against non-melanoma cells, which suggested the changes were specific for melanoma.
SINCE many of the earlier descriptions of in vitro cell-mediated cytotoxicity (CMC) against tumour cells by human blood mononuclear cells (e.g. Hellstrom et al., 1971) , there has been considerable controversy regarding the specificity and nature of the effector cells mediating the cytotoxicity (Baldwin, 1975; Herberman and Oldham, 1975; Takasugi et al., 1974) . There now appears to be a consensus of opinion that much of the cytotoxicity of mononuclear cells from blood of tumourbearing subjects is mediated by cells which are also found in non-tumourbearing subjects, and which have natural cytotoxic specificities for a wide range of tumour cells (Takasugi et al., 1974 (Takasugi et al., , 1977a Kiuchi and Takasugi, 1976; De Vries et al., 1975; Hersey et al., 1975b; West et al., 1977) .
Whether there are additional cytotoxic cells which are produced as part of a specific acquired immune response of the host to the tumour is still uncertain, although considerable support for such additional cytotoxic cells has been found in melanoma patients by a number of workers (De Vries and Rumpke 1976; Steele et al., 1976; Unsgaard and O'Toole, 1975; Mukherji et al., 1975) .
What is not clear from the existing studies is whether either form of CMC (i.e. naturally occurring or specific acquired) has any prognostic significance in regard to subsequent growth of the tumour. A number of studies in experimental animals has shown that both specific CMC (Kirchner et al., 1974; Kiessling et at., 1974) and naturally occurring CMC (Becker and Klein, 1976) 51Cr-release assays.-Full details of the assay procedure and expression of results have been described previously (Hersey et al., 1975a) . The melanoma target cell (TC) was the MM200 cell line obtained from Dr J. Pope of the Queensland Institute for Medical Research. This particular line was derived initially from a primary melanoma, and in previous studies was shown to react witlh a high proportion of melanoma antisera. Both "melanoma-specific" and "foetal-like" antigens have been defined on its surface. The control Chaing liver-cell line (Commonwealth Serum Laboratories, Melbourne, Victoria) was previously shown not to have, either melanoma or "foetal-like" antigens on its surface (Hersey et al., 1975b results suggest an association between low CMC values against cultured melanoma cells in patients after surgical removal of their melanoma and the subsequent recurrence of melanoma. One of the main problems in interpreting these results was to know the extent to which the patients were free of tumour after apparent complete surgical removal. This is important in that several previous studies, including those on CMC referred to in the introduction, have shown that various aspects of cell-mediated immunity appear to be suppressed as a result of tumour growth (Southam, 1968; Twomey et al., 1974; Anthony et al., 1975; Cochran et al., 1975; Oldham et al., 1976) .
This question is clearly difficult to resolve in the absence of reliable tumour marker assays in melanoma. However, we believe that suppression of CMC by preexisting tumour does not explain our results. Firstly, on clinical grounds there was no reason to believe that patients with low CMC had more residual tumour than those with high CMC. Secondly, most of the studies referred to have shown that depression of cell-mediated immunity occurred only in patients with advanced, clinically obvious, malignancies, and was not a feature of patients with localized disease. These points therefore argue against the low CMC being the result of pre-existing tumour, and suggest instead that the low CMC may have been one of the predisposing factors in development of recurrences in these patients. Natural CMC activity of blood mononuclear cells in mice has been shown to vary between strains and to be an inherited trait (Kiessling et al., 1975) . It is possible that the low levels of CMC of the blood mononuclear cells in the patients in this study may represent a similar group of subjects who have low levels of CMC on a genetic basis. The possible genetic basis of the low natural CMC is favoured by our recent findings that members of several families with a high incidence of melanoma had low or absent CMC against melanoma cells (manuscript in preparation).
The distribution of CMC values of melanoma patients against the melanoma TCs was different from that of the control subjects. This difference between the CMG of melanoma patients and control subjects was not evident against the control Chang TC and suggested that the specificities of natural CMC in the two groups were different. These results are compatible with recent studies showing that natural CMC does exhibit specificity to different tumour cells (Takasugi et al., 1977b; Bonnard et al., 1977) . Whether the difference in specificity of the CMC detected in our own studies was restricted to melanoma cells would require assays against a wider range of target cells than we have found practicable in routine studies.
Not all our findings, however, seem to be entirely explicable in terms of natural cytotoxicity by the blood mononuclear cells. The fall in CMC after the surgical removal of melanoma in the group with low CMC before surgery may have indicated a decrease in specific acquired CMC above the intrinsic low levels of natural CMC of the effector cells in these patients. The reason for the rise in CMC noted after surgery in the patients with high CMC before surgery is not immediately apparent, but may indicate that the CMC in these patients was suppressed by factors released by the growing tumour. Removal of the tumour may then have allowed the natural CMC to return to the former normally high levels. Whether or not the interpretation of these changes is correct, it is clear that these sequential changes were relatively specific to the melanoma cell, in that similar changes were not seen against the control Chang TC, and the natural CMC of normal subjects tested in parallel did not undergo similar changes against either target cell.
Relatively few studies have shown that immunological parameters have a prognostic bearing on the course of subsequent tumour growth in tumour patients. The classical study of Eilber and Morton (1970) showed that the ability of tumourbearing patients to be sensitized to dinitrochlorobenzene correlated with the subsequent course of tumour growth. These results, however, may have reflected the influence of the tumour on the skin test response and not the intrinsic immunological competence of the host. The studies of Twomey et al. (1974) would support this view, in that they found that "cured" cancer patients had skin-test reactivity similar to normal subjects and much higher than an equivalent group of patients before surgical removal of their tumour. Similarly, Hersh et al. (1975) using lymphocyte blastogenesis in response to melanoma antigens, found that the degree of blastogenic response to melanoma antigens could be correlated with the subsequent prognosis in patients with melanoma.
The study perhaps most analogous to our own was that of Veronesi et al. (1973) who correlated the results of microcytotoxicity tests on 18 Stage I & II melanoma patients with the duration to recurrence from melanoma. No correlation was found in this study between the presence or absence of CMC to melanoma and the duration to recurrence.
Whether our contention that the present results reflect the measurement of an intrinsic tumour-control mechanism is correct, obviously requires more extensive and prolonged studies of the melanoma patients, supported where possible by studies on families at risk from development of melanoma (Anderson, 1971) . If these initial findings were substantiated in these further studies, the present results would appear to have implications for immunotherapy of those patients detected to be at risk because of low natural CMC activity, in that therapeutic measures to increase the levels of CMC may be indicated in this group of patients. Measurement of natural CMC levels against melanoma cells may therefore provide the basis for a more selective and rational approach to immunotherapy of tumourbearing patients.
APPENDIX. 
